Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
HUTCHMED (China) ( (HK:0013) ) has provided an announcement.
HUTCHMED announced that it will present new and updated clinical data from several of its drug studies at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting. These presentations include results from studies on treatments for advanced solid tumors, renal cell carcinoma, pancreatic cancer, and non-small cell lung cancer, among others. The announcement highlights HUTCHMED’s ongoing efforts to advance its drug development pipeline and strengthen its position in the oncology and immunotherapy markets.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company operates primarily in China and collaborates with global partners to advance its drug pipeline.
Average Trading Volume: 7,392,446
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$19.43B
See more data about 0013 stock on TipRanks’ Stock Analysis page.